Frequency distribution of clinical and biologic features with respect to p-ERK1/2 expression
| . | p-ERK1/2 positive/total, no. (%) . | P . |
|---|---|---|
| Age, y | NS | |
| 16–30 | 14/45 (31.1) | |
| 31–60 | 31/86 (36.1) | |
| WBC | .013 | |
| Less than 50 × 109/L | 18/72 (25.0) | |
| 50 × 109/L or greater | 27/59 (45.8) | |
| Immunophenotype | NS | |
| B-ALL | 31/95 (32.6) | |
| T-ALL | 13/34 (38.2) | |
| .003 | ||
| CD34− less than 10% | 11/17 (64.7) | |
| CD34+ 10% or greater | 19/72 (26.4) | |
| Cytogenetic risk group | NS | |
| Standard low risk | 14/27 (51.9) | |
| Intermediate risk | 4/14 (28.6) | |
| High risk | 9/24 (37.5) | |
| Failure | 11/50 (22.0) | |
| Molecular genetics | NS | |
| BCR/ABL negative | 30/90 (33.3) | |
| BCR/ABL positive | 12/33 (36.4) | |
| t(4;11) negative | 34/94 (36.2) | |
| t(4;11) positive | 1/6 (16.7) | |
| Pretreatment responders | .099 | |
| Blasts less than 1000 | 18/65 (27.7) | |
| Blasts 1000 or greater | 15/34 (44.1) |
| . | p-ERK1/2 positive/total, no. (%) . | P . |
|---|---|---|
| Age, y | NS | |
| 16–30 | 14/45 (31.1) | |
| 31–60 | 31/86 (36.1) | |
| WBC | .013 | |
| Less than 50 × 109/L | 18/72 (25.0) | |
| 50 × 109/L or greater | 27/59 (45.8) | |
| Immunophenotype | NS | |
| B-ALL | 31/95 (32.6) | |
| T-ALL | 13/34 (38.2) | |
| .003 | ||
| CD34− less than 10% | 11/17 (64.7) | |
| CD34+ 10% or greater | 19/72 (26.4) | |
| Cytogenetic risk group | NS | |
| Standard low risk | 14/27 (51.9) | |
| Intermediate risk | 4/14 (28.6) | |
| High risk | 9/24 (37.5) | |
| Failure | 11/50 (22.0) | |
| Molecular genetics | NS | |
| BCR/ABL negative | 30/90 (33.3) | |
| BCR/ABL positive | 12/33 (36.4) | |
| t(4;11) negative | 34/94 (36.2) | |
| t(4;11) positive | 1/6 (16.7) | |
| Pretreatment responders | .099 | |
| Blasts less than 1000 | 18/65 (27.7) | |
| Blasts 1000 or greater | 15/34 (44.1) |
NS indicates not significant.